$AMGN Promising New Cancer Drug

WSJ headline: New Cancer Drug Beats Chemotherapy in Study

Sub-headline: Amgen’s Lumakras targets a mutation called KRAS that is common among many cancers

https://archive.ph/wip/E7VZm

Inflation rose more than expected in August even as prices moderated from four-decade highs reached earlier this year.

The Consumer Price Index (CPI) in August reflected an 8.3% increase over last year and a 0.1% increase over the prior month, the Bureau of Labor Statistics reported Tuesday. Economists had expected prices to rise 8.1% over last year and fall 0.1% over last month, according to estimates from Bloomberg.

On a “core” basis, which strips out the volatile food and energy components of the report, prices rose 6.3% over last year and 0.6% over the prior month in August.

1 Like

Let’s try cutting and pasting the correct body copy for this story

AP headline: New Cancer Drug Beats Chemotherapy in Study

Amgen’s Lumakras targets a mutation called KRAS that is common among many cancers

By Joseph Walker
Updated Sept. 12, 2022 4:52 pm ET

https://archive.ph/E7VZm

New data from the first of a new type of cancer drug suggest its benefits and limitations, while leaving room for other candidates seeking to enter the lucrative market.

Amgen Inc.’s lung-cancer pill Lumakras beat out a common chemotherapy in a late-stage study, helping patients survive without their tumors getting worse, though it failed to prove that it reduced overall deaths, the company said.

Lumakras is the first approved drug in an emerging class of treatments that target a genetic mutation called KRAS that is among the most common found in cancers. Researchers struggled for years to design drugs capable of attacking the mutation, which earned a reputation as “undruggable.”